HomeCompareFRSAF vs ABBV

FRSAF vs ABBV: Dividend Comparison 2026

FRSAF yields 16528.93% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRSAF wins by $7922109124184859648.00M in total portfolio value
10 years
FRSAF
FRSAF
● Live price
16528.93%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7922109124184859648.00M
Annual income
$7,828,934,889,822,254,000,000,000.00
Full FRSAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FRSAF vs ABBV

📍 FRSAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRSAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRSAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRSAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRSAF
Annual income on $10K today (after 15% tax)
$1,404,958.68/yr
After 10yr DRIP, annual income (after tax)
$6,654,594,656,348,915,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FRSAF beats the other by $6,654,594,656,348,915,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRSAF + ABBV for your $10,000?

FRSAF: 50%ABBV: 50%
100% ABBV50/50100% FRSAF
Portfolio after 10yr
$3961054562092429824.00M
Annual income
$3,914,467,444,911,127,000,000,000.00/yr
Blended yield
98.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FRSAF
No analyst data
Altman Z
68.6
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRSAF buys
0
ABBV buys
0
No recent congressional trades found for FRSAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRSAFABBV
Forward yield16528.93%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7922109124184859648.00M$102.3K
Annual income after 10y$7,828,934,889,822,254,000,000,000.00$24,771.77
Total dividends collected$7915950339545806848.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FRSAF vs ABBV ($10,000, DRIP)

YearFRSAF PortfolioFRSAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,663,593$1,652,892.56$11,550$430.00+$1.65MFRSAF
2$258,765,069$256,985,025.41$13,472$627.96+$258.75MFRSAF
3$37,634,801,464$37,357,922,840.00$15,906$926.08+$37634.79MFRSAF
4$5,118,154,945,422$5,077,885,707,855.37$19,071$1,382.55+$5118154.93MFRSAF
5$650,867,484,036,221$645,391,058,244,619.10$23,302$2,095.81+$650867484.01MFRSAF
6$77,400,481,231,577,040$76,704,053,023,658,290.00$29,150$3,237.93+$77400481231.55MFRSAF
7$8,607,646,413,813,204,000$8,524,827,898,895,416,000.00$37,536$5,121.41+$8607646413813.17MFRSAF
8$895,228,294,462,118,700,000$886,018,112,799,338,400,000.00$50,079$8,338.38+$895228294462118.75MFRSAF
9$87,078,723,703,369,350,000,000$86,120,829,428,294,890,000,000.00$69,753$14,065.80+$87078723703369360.00MFRSAF
10$7,922,109,124,184,860,000,000,000$7,828,934,889,822,254,000,000,000.00$102,337$24,771.77+$7922109124184859648.00MFRSAF

FRSAF vs ABBV: Complete Analysis 2026

FRSAFStock

First Au Limited explores for gold and base metals in Western Australia's Goldfields and Pilbara. It holds 100% interests in the Gimlet gold project located to the north west of Kalgoorlie, Western Australia; the Victoria Gold project; and the Mabel Creek project. The company was formerly known as Public Holdings (Australia) Limited and changed its name to First Au Limited in June 2018. First Au Limited was incorporated in 1960 and is based in Balwyn, Australia.

Full FRSAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FRSAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRSAF vs SCHDFRSAF vs JEPIFRSAF vs OFRSAF vs KOFRSAF vs MAINFRSAF vs JNJFRSAF vs MRKFRSAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.